|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FOXN2 |
Gene summary for FOXN2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FOXN2 | Gene ID | 3344 |
| Gene name | forkhead box N2 | |
| Gene Alias | HTLF | |
| Cytomap | 2p16.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P32314 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3344 | FOXN2 | LZE4T | Human | Esophagus | ESCC | 4.03e-09 | 2.98e-01 | 0.0811 |
| 3344 | FOXN2 | LZE7T | Human | Esophagus | ESCC | 4.90e-03 | 2.36e-01 | 0.0667 |
| 3344 | FOXN2 | LZE24T | Human | Esophagus | ESCC | 3.68e-09 | 2.48e-01 | 0.0596 |
| 3344 | FOXN2 | P2T-E | Human | Esophagus | ESCC | 2.66e-13 | 3.08e-01 | 0.1177 |
| 3344 | FOXN2 | P4T-E | Human | Esophagus | ESCC | 5.55e-07 | 2.40e-01 | 0.1323 |
| 3344 | FOXN2 | P5T-E | Human | Esophagus | ESCC | 5.38e-12 | 2.89e-01 | 0.1327 |
| 3344 | FOXN2 | P8T-E | Human | Esophagus | ESCC | 6.60e-07 | 6.23e-02 | 0.0889 |
| 3344 | FOXN2 | P9T-E | Human | Esophagus | ESCC | 1.66e-10 | 3.14e-01 | 0.1131 |
| 3344 | FOXN2 | P10T-E | Human | Esophagus | ESCC | 3.93e-11 | 8.63e-02 | 0.116 |
| 3344 | FOXN2 | P11T-E | Human | Esophagus | ESCC | 2.58e-04 | 2.54e-01 | 0.1426 |
| 3344 | FOXN2 | P12T-E | Human | Esophagus | ESCC | 3.18e-06 | 9.55e-02 | 0.1122 |
| 3344 | FOXN2 | P15T-E | Human | Esophagus | ESCC | 2.65e-04 | 1.27e-01 | 0.1149 |
| 3344 | FOXN2 | P16T-E | Human | Esophagus | ESCC | 1.38e-11 | 1.44e-01 | 0.1153 |
| 3344 | FOXN2 | P19T-E | Human | Esophagus | ESCC | 9.32e-05 | 4.37e-01 | 0.1662 |
| 3344 | FOXN2 | P20T-E | Human | Esophagus | ESCC | 5.45e-16 | 4.31e-01 | 0.1124 |
| 3344 | FOXN2 | P21T-E | Human | Esophagus | ESCC | 1.16e-13 | 2.59e-01 | 0.1617 |
| 3344 | FOXN2 | P22T-E | Human | Esophagus | ESCC | 3.48e-12 | 1.67e-01 | 0.1236 |
| 3344 | FOXN2 | P23T-E | Human | Esophagus | ESCC | 1.15e-06 | 2.93e-01 | 0.108 |
| 3344 | FOXN2 | P24T-E | Human | Esophagus | ESCC | 1.60e-11 | 1.91e-01 | 0.1287 |
| 3344 | FOXN2 | P26T-E | Human | Esophagus | ESCC | 7.54e-23 | 4.14e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
| GO:001470615 | Esophagus | ESCC | striated muscle tissue development | 197/8552 | 384/18723 | 1.46e-02 | 4.74e-02 | 197 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| FOXN2 | END | Colorectum | SER | RGS6,RAB20,LINC00649, etc. | 5.59e-01 |  |
| FOXN2 | END | Lung | AIS | DCLK1,RAB2B,MTFR1, etc. | 6.24e-02 |  |
| FOXN2 | ADIPO | Lung | Healthy | DCLK1,RAB2B,MTFR1, etc. | 0.00e+00 |  |
| FOXN2 | MSC.MVA | Lung | Healthy | DCLK1,RAB2B,MTFR1, etc. | 1.02e-02 | |
| FOXN2 | MYOFIB | Lung | Healthy | DCLK1,RAB2B,MTFR1, etc. | 2.22e-16 | |
| FOXN2 | END | Lung | IAC | DCLK1,RAB2B,MTFR1, etc. | 3.33e-02 |  |
| FOXN2 | CD8TEXP | Oral cavity | ADJ | SLC35F1,RIC1,FLT3, etc. | 2.78e-02 |  |
| FOXN2 | CD4TN | Oral cavity | ADJ | SLC35F1,RIC1,FLT3, etc. | 1.65e-02 | |
| FOXN2 | M1MAC | Oral cavity | EOLP | SLC35F1,RIC1,FLT3, etc. | 7.22e-02 |  |
| FOXN2 | M1MAC | Oral cavity | NEOLP | SLC35F1,RIC1,FLT3, etc. | 8.34e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FOXN2 | SNV | Missense_Mutation | c.787N>T | p.Pro263Ser | p.P263S | P32314 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FOXN2 | SNV | Missense_Mutation | rs368231934 | c.768N>C | p.Leu256Phe | p.L256F | P32314 | protein_coding | tolerated(0.91) | probably_damaging(0.916) | TCGA-BH-A0GZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| FOXN2 | insertion | Frame_Shift_Ins | novel | c.1120_1121insGC | p.Lys374SerfsTer42 | p.K374Sfs*42 | P32314 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| FOXN2 | insertion | Frame_Shift_Ins | novel | c.1121_1122insTT | p.Lys374AsnfsTer2 | p.K374Nfs*2 | P32314 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| FOXN2 | SNV | Missense_Mutation | novel | c.1112C>G | p.Pro371Arg | p.P371R | P32314 | protein_coding | tolerated(0.32) | benign(0.03) | TCGA-5M-AAT4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| FOXN2 | SNV | Missense_Mutation | rs763008415 | c.503A>C | p.Lys168Thr | p.K168T | P32314 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FOXN2 | SNV | Missense_Mutation | rs377347494 | c.1231N>T | p.Arg411Cys | p.R411C | P32314 | protein_coding | deleterious(0) | possibly_damaging(0.72) | TCGA-AY-5543-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | oxaliplatin | SD |
| FOXN2 | SNV | Missense_Mutation | novel | c.316N>C | p.Lys106Gln | p.K106Q | P32314 | protein_coding | tolerated(0.08) | benign(0.037) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| FOXN2 | SNV | Missense_Mutation | novel | c.872N>A | p.Ser291Tyr | p.S291Y | P32314 | protein_coding | deleterious(0) | benign(0.28) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| FOXN2 | SNV | Missense_Mutation | c.280N>T | p.Pro94Ser | p.P94S | P32314 | protein_coding | tolerated(0.31) | benign(0.003) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |